Cunningham Hit Ground Running When It Came To Tamping Down on Drug Prices

December 4, 2019 by Dan McCue
Cunningham Hit Ground Running When It Came To Tamping Down on Drug Prices

WASHINGTON – In the Lowcountry of South Carolina, Rep. Joe Cunningham’s race for Congress quickly became the stuff of local legend.

Here was a first-time candidate, a Democrat running in a staunchly Republican district, who defeated a well-financed GOP opponent, to become the first Democratic representative from South Carolina’s 1st Congressional District since 1981.

But the ever-energetic congressman didn’t stop there. Almost as soon as he arrived in Washington, at a time when many newcomers were still losing their way in the Capitol’s winding hallways, he was looking to fulfill some important campaign promises.

The first was filing a bill to ban offshore oil and gas exploration off the South Carolina coast. Soon thereafter, he actively joined efforts in the House to lower the cost of prescription drugs.

“One of my earliest constituent meetings was with Lowcountry parents who struggle to afford life-saving insulin for their children,” Cunningham recently said of the urgency he felt.

“In the last five years, the cost of one of the most common brands of insulin has increased from $2,907 a year to more than $4,700 a year. Meetings like these reaffirm to me how urgent this issue is,” he said.

In May, he voted in favor of H.R. 986, a bipartisan bill designed to strengthen protections for people with pre-existing conditions, an effort to buttress the Affordable Care Act against administration efforts to weaken it.

He followed up that vote, by introducing the CLAY Act, which would lower the cost of prescription drugs for beneficiaries who receive the low-income subsidy (LIS) in Medicare Part D.

More recently, Cunningham joined with fellow members of the Blue Dog Coalition of moderate House Democrats to endorse a series of prescription drug pricing bills that they believe, if taken up individually, could pass a Democratic-led House and a Republican-led Senate.

They include the CREATES Act and BLOCKING Act, bills aimed at helping generic drug makers bring their products to market more quickly while also lifting barriers to competition.

Cunningham told The Well News that when it comes to the issue of drug pricing, he expects meaningful results to be achieved, even against the headwinds of the ongoing impeachment proceedings and the impending 2020 political campaigns.

“Of course I do,” he said.

“My top priority in Congress is to serve the people of the Lowcountry and I know that my colleagues on both sides of the aisle feel the same way about their districts and their constituents,” Cunningham said.

“Lowering the cost of prescription drugs isn’t a Democratic or Republican issue – it’s an American one,” he added.

“Frankly, this issue is far beyond politics, this is about quality of life,” he said. “Nearly 3-in-10 South Carolinians have reported that they’ve had to stop taking medication as prescribed because of cost in the last year,” he said. “We need to get this legislation signed into law as soon as possible for them – and for folks across the nation.”

A+
a-
  • Joe Cunningham
  • prescription drug prices
  • In The News

    Health

    Voting

    Prescription Drugs

    April 17, 2024
    by Dan McCue
    Eli Lilly Obesity Drug Appears to Ease Sleep Apnea Symptoms in Trials

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its... Read More

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its obesity drug, Zepbound, can provide considerable relief to overweight people who have sleep apnea. Though the findings have yet to be published in a peer-reviewed medical... Read More

    Many Cancer Drugs Remain Unproven Five Years After Accelerated Approval, a Study Finds

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often... Read More

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such... Read More

    ALS Drug Will Be Pulled From US Market After Study Showed Patients Didn't Benefit

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it... Read More

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and... Read More

    April 3, 2024
    by Dan McCue
    FDA Approves New Antibiotic for Three Different Uses

    WASHINGTON — The Food and Drug Administration on Wednesday approved the drug Zevtera for the treatment of adults with certain... Read More

    WASHINGTON — The Food and Drug Administration on Wednesday approved the drug Zevtera for the treatment of adults with certain bloodstream infections, those with acute bacterial skin and skin structure infections, and adult and pediatric patients 3 months to less than 18 years old with community-acquired... Read More

    Biden and Harris Team Up for Health Care Event in North Carolina

    WASHINGTON (AP) — President Joe Biden and Vice President Kamala Harris will promote their health care agenda on Tuesday in... Read More

    WASHINGTON (AP) — President Joe Biden and Vice President Kamala Harris will promote their health care agenda on Tuesday in North Carolina, a battleground state that Democrats hope to flip in their favor after falling short to Donald Trump in the last two presidential elections. Fourteen... Read More

    March 13, 2024
    by Dan McCue
    FDA Believed Poised to Approve First Med for a Serious Liver Disease

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious... Read More

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious liver disease known as MASH later this week.  Metabolic dysfunction-associated steatohepatitis -- formerly known as nonalcoholic steatohepatitis — is often associated with obesity. In patients who... Read More

    News From The Well
    scroll top